Akero Therapeutics (AKRO)
(Delayed Data from NSDQ)
$26.41 USD
+0.06 (0.23%)
Updated Sep 6, 2024 04:00 PM ET
After-Market: $26.41 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth B Momentum F VGM
Cash flow Statements
Fiscal Year End for Akero Therapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -151.76 | -112.03 | -100.78 | -79.21 | -43.76 |
Depreciation/Amortization & Depletion | -9.08 | 0.24 | 1.11 | 0.10 | -0.10 |
Net Change from Assets/Liabilities | -6.67 | -4.46 | 9.73 | 2.09 | 6.46 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 22.14 | 23.74 | 10.26 | 6.22 | 1.77 |
Net Cash From Operating Activities | -145.37 | -92.52 | -79.68 | -70.80 | -35.63 |
Property & Equipment | 0.00 | 0.00 | 0.00 | -0.15 | 0.00 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | -223.62 | -63.83 | 42.28 | -9.61 | -71.51 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | -223.62 | -63.83 | 42.28 | -9.76 | -71.51 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 339.09 | 246.50 | 1.12 | 203.06 | 95.99 |
Issuance (Repayment) of Debt | 15.00 | 10.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -0.78 | -0.86 | -0.52 | 0.05 | 0.00 |
Net Cash from Financing Activities | 353.32 | 255.63 | 0.60 | 203.11 | 95.99 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -15.67 | 99.29 | -36.80 | 122.54 | -11.15 |
Cash at Beginning of Period | 249.88 | 150.59 | 187.39 | 64.85 | 76.00 |
Cash at End of Period | 234.21 | 249.88 | 150.59 | 187.39 | 64.85 |
Diluted Net EPS | -2.89 | -2.87 | -2.89 | -2.52 | -2.90 |
Fiscal Year End for Akero Therapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -109.33 | -53.34 | -151.76 | -96.57 | -56.91 |
Depreciation/Amortization & Depletion | -6.10 | -2.81 | -9.08 | -5.55 | -2.41 |
Net Change from Assets/Liabilities | 6.19 | 13.08 | -6.67 | -10.60 | 2.11 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 16.65 | 7.94 | 22.14 | 15.98 | 10.18 |
Net Cash From Operating Activities | -92.59 | -35.14 | -145.37 | -96.74 | -47.02 |
Property & Equipment | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | -197.05 | 57.85 | -223.62 | -236.41 | -110.71 |
Other Investing Activities | -1.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | -198.05 | 57.85 | -223.62 | -236.41 | -110.71 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 357.54 | 357.21 | 339.09 | 338.56 | 337.75 |
Issuance (Repayment) of Debt | 10.00 | 10.00 | 15.00 | 15.00 | 15.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -0.75 | -0.27 | -0.78 | -0.75 | -0.75 |
Net Cash from Financing Activities | 366.79 | 366.94 | 353.32 | 352.81 | 352.01 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | 76.15 | 389.65 | -15.67 | 19.67 | 194.28 |
Cash at Beginning of Period | 234.21 | 234.21 | 249.88 | 249.88 | 249.88 |
Cash at End of Period | 310.36 | 623.85 | 234.21 | 269.55 | 444.16 |
Diluted Net EPS | -0.81 | -0.90 | -1.03 | -0.71 | -0.60 |